Experimental HIV vaccine regimen safe but ineffective, NIH study finds
17 Articles
17 Articles
U.S. experimental HIV vaccine regimen safe but ineffective: study
LOS ANGELES, Jan. 18 (Xinhua) -- A U.S. investigational HIV vaccine regimen was safe but did not provide protection against HIV acquisition, according to a release of the U.S. National Institute of Health (NIH) on Wednesday. Read full story
Experimental HIV vaccine regimen safe but ineffective
An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined. The HPX3002/HVTN 706, or 'Mosaico,' Phase 3 clinical trial began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America. Based on the DSMB's recommendation, the…
Coverage Details
Bias Distribution
- 70% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage